Based on these findings, we hypothesize that breast cancer patients with the C2 phenotype exhibit low expression of CCL19, contributing to the creation of an immunosuppressive microenvironment and subsequently leading to poor patient outcomes. Here, CCL19 is linked to breast carcinoma.